- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02355769
Complex Pathophysiological Background of Heart Failure Deterioration
Multiparametric Assessment of Complex Pathophysiological Background of Heart Failure Deterioration - Relation to Treatment Effects and Prognosis
연구 개요
상태
정황
상세 설명
PURPOSE:
Treatment of patients with heart failure (HF) is a great challenge for contemporary medicine. HF frequency in European population is assessed for 0.4 - 2%. This disease is characterized by high morbidity and mortality rate, poor quality of life and the necessity of frequent hospitalizations. Along with the medicine progress, in particular in the scope of acute coronary syndromes treatment, the number of HF patients is constantly growing. The essential problem connected with HF is its progress course and an increasing frequency of subsequent hospitalizations (approximately 30% of hospitalizations are the repeated ones). It is estimated that the costs of hospital stays constitute nearly 2/3 of healthcare costs provided for HF patients. In the United States approximately 50% of HF patients have been rehospitalized within 6 months from discharge and 70% of these hospitalizations were caused by HF deterioration.The prognosis in HF is closely connected with the progression of the disease defined in accordance with the NYHA (New York Heart Association) functional classification. The yearly mortality rate among each NYHA class is: class 1 - up to 10%, class 2 - 10-20%, class 3 - 20-40%, class 4 - mortality 40-60%. Over half of the patients with symptomatic HF die within 4 years of observation The high in-hospital mortality has been a great problem and results not only from the natural history of HF progression, but also from a number of coexisting complications (i.e. aggravation of ischaemic heart disease, lung diseases, infections, electrolyte disturbances, anaemia, renal failure as well as operations, in particular emergency ones). The optimal schemes of identifying the individual risk are of fundamental importance to guide the safe therapy. Undoubtedly hemodynamic status and its change during hospitalization is one of the main predictive factors of treatment response and occurrences of adverse effects of therapy, i.e. renal function worsening. However, there are no clear guidelines on how to perform safe and effective non-invasive hemodynamic monitoring.
AIMS:
The evaluation of complex pathophysiological features related to heart failure deterioration, including the parameters characterizing i.e. cardiovascular hemodynamics, hydration status, renal failure, iron metabolism and gas exchange, with respect to the effect of applied in-hospital treatment The evaluation of clinical value of the parameters characterizing i.e. cardiovascular hemodynamics, hydration status, renal failure, iron metabolism and gas exchange in prognosis of patients with heart failure deterioration
METHODS:
All the recruited patients will undergo the following assessment:
Clinical examination Laboratory tests, ncluding i.e. white blood cells count, red blood cells count, hemoglobin, hematocrit, mean cell volume (MCV), red cell distribution width (RDW); sodium, potassium, creatinine, estimated glomerular filtration rat (eGFR), urea, cystatin C; fasting glucose; bilirubin; total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, N-terminal of the prohormone brain natriuretic peptide (NT-proBNP); hs-TnT (high sensitive troponin T), iron; ferritin; unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC), transferrin saturation, soluble transferrin receptor; pH, carbon dioxide partial pressure (pCO2), oxygen partial pressure (pO2), arterial oxygen saturation (SaO2), bicarbonate content (HCO3-), base excess (BE), lactates; thyroid-stimulating hormone (TSH), testosterone, dehydroepiandrosterone sulfate (DHEAS), estradiol Electrocardiogram Echocardiography Chest X-ray Holter-ekg monitoring ambulatory blood pressure monitoring impedance cardiography (including assessment of: resting heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC), cardiac index (CI), stroke index (SI), systemic vascular resistance index (SVRI) bioimpedance (including assessment total body water (TBW), intracellular and extracellular water (ICW, ECW)) applanation tonometry (including assessment of augmentation index (AI) and central pulse pressure (CPP))
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Mazovia
-
Warsaw, Mazovia, 폴란드, 04-141
- Military Institute of Medicine
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- patients of either sex
- urgent hospitalization caused by deterioration of HF.
Exclusion Criteria:
- unstable coronary artery disease including myocardial infarct within the last 40 days prior to recruitment
- stroke within 40 days prior to recruitment
- cardiac surgery within 90 days prior to recruitment
- pulmonary embolism
- severe pulmonary diseases (chronic obstructive pulmonary diseases - stage C/D, uncontrolled asthma, pulmonary hypertension)
- chronic kidney disease (stage 5 and requiring dialysis)
- severe inflammatory disease
- severe mental and physical disorders
- patients' refusal to participate
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
in-hospital death
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
combined primary endpoint (in-hospital death and/or myocardial infract and/or stroke and/or serious arrhythmia and/or worsening renal function)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
myocardial infract
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
stroke (clinical symptoms and confirmed in CT)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
serious arrhythmia (new onset sustained ventricular tachycardia/fibrillation, supraventricular tachycardia, atrial fibrillation/flutter, sustained bradycardia <40/min)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
worsening renal function (increase in creatinine 0,3mg/dl according to the definition of AKDI)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
significant electrolyte disturbances (K <3,0mmol/l; Na < 120mmol/l and or change in Na 10 mmol/l)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
symptomatic hypotension (SBP <90 mmHg or change in40 mmHg)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
hospitalization time (days)
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in NYHA class
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
"diuretic effectiveness ratio" - change in body mass change [%]/diuretics use [mg]
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in HR
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in SBP
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in DBP
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in SI
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in CI
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in TFC
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in SVRI
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in body mass
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in TBW
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in ECW
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in ICW
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in bilirubin
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in eGFR
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in urea
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in hemoglobin
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in hematocrit
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in NTproBNP
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in pH
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
change in lactates
기간: 8 days
|
time frame - assumed mean time of hospitalization
|
8 days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Pawel Krzesinski, MD, PhD, Military Institute of Medicine
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심부전에 대한 임상 시험
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University of... 그리고 다른 협력자들아직 모집하지 않음심부전, 수축기 | 박출률이 감소된 심부전 | 심부전 New York Heart Association Class IV | 심부전 New York Heart Association Class III폴란드
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
University of WashingtonAmerican Heart Association완전한심부전,울혈 | 미토콘드리아 변경 | 심부전 New York Heart Association Class IV미국